Vertex Pharmaceuticals Logo

Email this page: News Release

FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation

For security reasons, registration is required before you can use this feature.
* Indicates required field